How do you pay?

How to pay the least

Ask for the cash price

Tadliq

Sold only in a different form, strength or formula. Switching to one would need a new prescription, so ask your prescriber whether it could work for you.

  1. Ask your pharmacy for Tadliq’s cash price, and one or two other pharmacies too.
  2. Tadliq’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameTadliq
Authorized generictadalafil
Regular generictadalafil
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Other forms onlyAsk your doctor
Same as Tadliq?
The original
–
–

Brand nameThe maker’s card

CMP EasyPay Copay Card

Savings card from CMP Pharma

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on easypaysavings.com 

Or call 1-844-567-9503.

In the maker’s words

“pay as little as $0 up to the maximum benefit.”

From the maker’s offer on easypaysavings.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Tadliq itself, from the same company, sold without the brand name, and usually for less. For now Tadliq is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Sold only in a different form, strength or formula. Switching to one would need a new prescription, so ask your prescriber whether it could work for you. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

TADLIQ is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).

Source: the FDA label for Tadliq (CMP Pharma, Inc.), October 15, 2022. Full label on DailyMed 

Good to know